Back to Search Start Over

Decrease in functional activity of G-proteins hormone-sensitive adenylate cyclase signaling system, during experimental type II diabetes mellitus.

Authors :
Shpakov AO
Kuznetsova LA
Plesneva SA
Bondareva VM
Guryanov IA
Vlasov GP
Pertseva MN
Source :
Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2006 Dec; Vol. 142 (6), pp. 685-9.
Publication Year :
2006

Abstract

The development of experimental type II diabetes mellitus in rats was accompanied by dysfunction of inhibitory and stimulatory heterotrimeric G-proteins, components of hormone-sensitive adenylate cyclase signal system. The function of inhibitory G-proteins decreased most significantly under these conditions, which is seen from weakened regulatory effects of somatostatin (in the myocardium) and bromocriptine (in the brain striatum) realized via inhibitory G-proteins in diabetic rats compared to controls. These hormones produce less pronounced inhibitory effect on forskolin-induced activation of adenylate cyclase. In the myocardium of diabetic rats, the stimulatory effects of isoproterenol and relaxin on adenylate cyclase realized via stimulatory G-proteins were decreased to a lesser extent. In the striatum of diabetic rats the stimulatory effect of serotonin and relaxin did not differ from the control. Therefore, dysfunction of stimulatory G-proteins during type II diabetes mellitus is characterized by tissue specificity. Synthetic peptides corresponding to functionally important regions in a-subunits of G-proteins and relaxin receptor LGR7 less effectively inhibited hormone signal transduction via the adenylate cyclase system in rats with type II diabetes. These changes reflect abnormal coupling between receptors and G-proteins in tissues of diabetic rats.

Details

Language :
English; Russian
ISSN :
0007-4888
Volume :
142
Issue :
6
Database :
MEDLINE
Journal :
Bulletin of experimental biology and medicine
Publication Type :
Academic Journal
Accession number :
17603670
Full Text :
https://doi.org/10.1007/s10517-006-0451-2